Poniard Pharmaceuticals (Poniard Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 77.41% (As of Apr. 29, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Poniard Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Poniard Pharmaceuticals's float shares is 1.16 Mil. Poniard Pharmaceuticals's total shares outstanding is 1.50 Mil. Poniard Pharmaceuticals's float percentage of total shares outstanding is 77.41%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Poniard Pharmaceuticals's Insider Ownership is 2.31%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Poniard Pharmaceuticals's Institutional Ownership is 0.00%.

Poniard Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Poniard Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	1.16	/	1.50
	=	77.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poniard Pharmaceuticals Inc (OTCPK:PARD) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119

Website

http://www.poniard.com

Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.

Executives

Michael S Perry	officer: President & CMO	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Ron Martell	director, officer: Chief Executive Officer	PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gary A Lyons	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
David R Stevens	director	300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Gerald Phd Mcmahon	director	300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Carl Goldfischer	director	161 WEST 61ST STREET, NEW YORK NY 10022
Fred B Craves	director	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Simon Nicholas J Iii	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Gregory L Weaver	officer: Chief Financial Officer	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Kurt Wheeler	10 percent owner	801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080
Mpm Asset Management Investors 2005 Bviii Llc	10 percent owner	C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199
Nicholas Galakatos	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Dennis Henner	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Michael Steinmetz	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Luke Evnin	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Headlines

From GuruFocus

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-10-2010

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 08-09-2010

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-06-2009

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 05-12-2009

Poniard Pharmaceuticals Inc. (PARD) CFO Gregory L Weaver buys 2,000 Shares

By gurufocus • 04-06-2009

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-07-2009

Poniard Pharmaceuticals Inc. (PARD) CFO Gregory L Weaver buys 3,000 Shares

By GuruFocus Research GuruFocus Editor • 08-22-2009